Patents by Inventor Caroline Elaine Porter

Caroline Elaine Porter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11896634
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: February 13, 2024
    Assignee: Baylor College Of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner
  • Publication number: 20220387530
    Abstract: The present disclosure concerns combination therapy for cancer thatutilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Application
    Filed: November 7, 2019
    Publication date: December 8, 2022
    Applicant: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner, Andrew Sikora
  • Publication number: 20200323932
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Application
    Filed: April 20, 2018
    Publication date: October 15, 2020
    Applicant: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner
  • Patent number: 10716818
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor, and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: July 21, 2020
    Assignee: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner
  • Publication number: 20190374589
    Abstract: The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor, and (iii) at least one cell comprising a chimeric antigen receptor (CAR) specific for a cancer cell antigen. In particular embodiments, the virus comprises nucleic acid encoding an immunomodulatory factor comprises nucleic acid encoding IL-12 and/or antagonist anti-PD-L1 antibody.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 12, 2019
    Applicant: Baylor College of Medicine
    Inventors: Masataka Suzuki, Amanda Rosewell Shaw, Caroline Elaine Porter, Norihiro Watanabe, Malcolm K. Brenner